Using New Insulin Strategies in the Outpatient Treatment of Diabetes Clinical Applications

JAMA

Volumn 289, Issue 17, 2003, Pages 2265-2269

  DeWitt, Dawn E ^a,b   Dugdale, David C ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; PREDNISOLONE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG COST; FEMALE; GIANT CELL ARTERITIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; MALE; OUTPATIENT CARE; POSTPRANDIAL STATE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN; ARTICLE; BLOOD; CASE REPORT; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED;

EID: 0038147377     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.17.2265     Document Type: Review

References (22)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
3. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;(23 suppl 2):B21-29.
4. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997;314:1512-1515.
5. Saaddine JB, Engelgau MM, Beckless GL, Gregg EW, Thompson TJ, Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med. 2002;136:565-574.
6. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donely DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24: 631-636.
7. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Hekkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med. 1999; 130:389-396.
8. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes: HOE 901/3002 Study Group. Diabetes Care. 2000;23:1130-1136.
9. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes: US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000;23:639-643.
10. Annuzzi G, Del Prato S, Arcari R, et al. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. Nutr Metab Cardiovasc Dis. 2001;11:168-175.
11. Holmboe ES. Oral antihyperglycemic therapy for type 2 diabetes: clinical applications. JAMA. 2002; 287:373-376.
12. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR, the UK Prospective Diabetes Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-336.
13. Malone JK, Yang H, Woodworth JR, et al. Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. Diabetes Metab. 2000;26:481-487.
14. Malone JK, Woodworth JR, Arora V, et al. Improved postprandial glycemic control with Humalog Mix75/25 aftera standard test meal in patients with type 2 diabetes mellitus. Clin Ther. 2000;22:222-230.
15. Roach P, Strack T, Arora V, Zhao Z. Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. Int J Clin Pract. 2001;55:177-182.
16. Abraira C, Henderson WG, Colwell JA, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes: VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care. 1998;21:574-579.
17. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): results of the feasibility trial: Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care. 1995;18:1113-1123.
18. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care. 1993;16:21-31.
19. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med. 2001;18:619-625.
20. Muhlhauser I, Bott U, Overman H, et al. Liberalized diet in patients with type 1 diabetes. J Intern Med. 1995;237:591-597.
21. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26 (suppl 1):S33-S50.
22. Trence DL. Management of complications of glucocorticoids, an endocrine perspective. Primary Care; Clinics in Office Practice. In press.